LONNE Stock Overview
Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Lonza Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 523.40 |
| 52 Week High | CHF 589.00 |
| 52 Week Low | CHF 316.80 |
| Beta | 0.64 |
| 11 Month Change | -5.90% |
| 3 Month Change | -5.18% |
| 1 Year Change | 51.36% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| LONNE | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 2.5% | 2.1% | 0.6% |
| 1Y | 51.4% | 32.2% | 6.4% |
Return vs Industry: LONNE exceeded the Swiss Life Sciences industry which returned 30.1% over the past year.
Return vs Market: LONNE exceeded the Swiss Market which returned 5.8% over the past year.
Price Volatility
| LONNE volatility | |
|---|---|
| LONNE Average Weekly Movement | 3.3% |
| Life Sciences Industry Average Movement | 4.2% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 6.6% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: LONNE has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: LONNE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 17,834 | Wolfgang Wienand | www.lonza.com |
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.
Lonza Group AG Fundamentals Summary
| LONNE fundamental statistics | |
|---|---|
| Market cap | CHF 37.66b |
| Earnings (TTM) | CHF 573.00m |
| Revenue (TTM) | CHF 6.70b |
65.7x
P/E Ratio5.6x
P/S RatioIs LONNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LONNE income statement (TTM) | |
|---|---|
| Revenue | CHF 6.70b |
| Cost of Revenue | CHF 4.29b |
| Gross Profit | CHF 2.41b |
| Other Expenses | CHF 1.84b |
| Earnings | CHF 573.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Jan 29, 2025
| Earnings per share (EPS) | 7.93 |
| Gross Margin | 36.01% |
| Net Profit Margin | 8.56% |
| Debt/Equity Ratio | 40.3% |
How did LONNE perform over the long term?
See historical performance and comparison